HIV-1 protease inhibitors (PIs) have long been central to antiretroviral therapy, directly targeting the enzyme responsible for processing viral polyproteins into functional units. Their efficacy, ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...